Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Report of a workshop on ensuring sustainable access to safe blood in developing countries: International Blood Safety Forum, March 24, 2017.

Katz LM, Donnelly JJ, Gresens CJ, Holmberg JA, MacPherson J, Zacharias PJK, Stanley J, Bales C.

Transfusion. 2018 May;58(5):1299-1306. doi: 10.1111/trf.14591. Epub 2018 Mar 14. Review.

PMID:
29542121
2.

Universal influenza vaccines: Shifting to better vaccines.

Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ.

Vaccine. 2016 Jun 3;34(26):2926-2933. doi: 10.1016/j.vaccine.2016.03.085. Epub 2016 Mar 31.

3.

Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries.

Mahmood K, Pelkowski S, Atherly D, Sitrin RD, Donnelly JJ.

Hum Vaccin Immunother. 2013 Sep;9(9):1894-902. doi: 10.4161/hv.25407. Epub 2013 Jun 20. Review.

4.

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R.

Lancet Infect Dis. 2013 May;13(5):416-25. doi: 10.1016/S1473-3099(13)70006-9. Epub 2013 Feb 13.

PMID:
23414709
5.

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.

Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, Ledroit M, Hong E, Taha MK, Ellie K, Rajam G, Carlone GM, Claus H, Vogel U, Borrow R, Findlow J, Gilchrist S, Stefanelli P, Fazio C, Carannante A, Oksnes J, Fritzsønn E, Klem AM, Caugant DA, Abad R, Vázquez JA, Rappuoli R, Pizza M, Donnelly JJ, Medini D.

Clin Vaccine Immunol. 2012 Oct;19(10):1609-17. Epub 2012 Aug 8.

6.

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.

Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, Muzzi A, Pizza M, Rappuoli R, Donnelly JJ, Giuliani MM, Serruto D.

Vaccine. 2011 Jan 29;29(5):1072-81. doi: 10.1016/j.vaccine.2010.11.064. Epub 2010 Dec 3.

PMID:
21130753
7.

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans.

Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, O'Dwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Aricò B.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3770-5. doi: 10.1073/pnas.0915162107. Epub 2010 Feb 3.

8.

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.

Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B.

Vaccine. 2009 Oct 9;27(43):5998-6003. doi: 10.1016/j.vaccine.2009.07.079. Epub 2009 Aug 7.

PMID:
19665606
9.

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, Rabussay D, Zhang L, Ulmer JB, Barnett SW, Donnelly JJ.

AIDS Res Hum Retroviruses. 2008 Aug;24(8):1103-16. doi: 10.1089/aid.2008.0055.

10.

Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery.

Goodsell A, Zhou F, Gupta S, Singh M, Malyala P, Kazzaz J, Greer C, Legg H, Tang T, Zur Megede J, Srivastava R, Barnett SW, Donnelly JJ, Luciw PA, Polo J, O'Hagan DT, Vajdy M.

Immunology. 2008 Mar;123(3):378-89. Epub 2007 Oct 17.

11.

Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.

Gupta S, Zhou F, Greer CE, Legg H, Tang T, Luciw P, zur Megede J, Barnett SW, Donnelly JJ, O'Hagan DT, Polo JM, Vajdy M.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):993-7.

PMID:
17067269
12.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

13.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
14.

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

Barnett SW, Srivastava IK, Ulmer JB, Donnelly JJ, Rappuoli R.

Microbes Infect. 2005 Nov;7(14):1386-91. Epub 2005 Sep 20.

PMID:
16275150
15.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

16.

DNA vaccines: progress and challenges.

Donnelly JJ, Wahren B, Liu MA.

J Immunol. 2005 Jul 15;175(2):633-9. Review.

17.

Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles.

Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan DT, Donnelly JJ 3rd, Ott G, McDonald DM.

Cell Immunol. 2003 Sep;225(1):12-20.

PMID:
14643300
18.

Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

zur Megede J, Otten GR, Doe B, Liu H, Leung L, Ulmer JB, Donnelly JJ, Barnett SW.

J Virol. 2003 Jun;77(11):6197-207.

19.

Envelope-based HIV vaccines.

Donnelly JJ, Barnett SW, Dorenbaum A, Stamatatos L.

Science. 2002 Aug 23;297(5585):1277-8; author reply 1277-8. No abstract available.

PMID:
12194177
20.

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, Barnett SW.

J Virol. 2002 Mar;76(6):2835-47.

21.

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells.

Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G.

Gene Ther. 2000 Dec;7(24):2105-12.

22.
23.

Antigen presentation and DNA vaccines.

Donnelly JJ, Liu MA, Ulmer JB.

Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 2):S190-3. Review.

PMID:
11029393
24.

Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice.

Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM.

J Immunol. 2000 Sep 1;165(5):2850-8.

26.

Blocking bacterial enterotoxins.

Donnelly JJ, Rappuoli R.

Nat Med. 2000 Mar;6(3):257-8. No abstract available.

PMID:
10700222
27.

Enhancement of DNA vaccine potency using conventional aluminum adjuvants.

Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, Caulfield MJ, Bohannon KE, Volkin DB, Evans RK.

Vaccine. 1999 Aug 20;18(1-2):18-28.

PMID:
10501231
28.

DNA vaccines for viral diseases.

Donnelly JJ, Ulmer JB.

Braz J Med Biol Res. 1999 Feb;32(2):215-22. Review.

PMID:
10347757
29.

Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.

Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ.

J Immunol. 1999 Apr 1;162(7):4163-70.

30.

DNA vaccines. Mechanisms for generation of immune responses.

Liu MA, Fu TM, Donnelly JJ, Caulfield MJ, Ulmer JB.

Adv Exp Med Biol. 1998;452:187-91. Review. No abstract available.

PMID:
9889973
31.

DNA vaccines.

Donnelly JJ, Ulmer JB, Liu MA.

Dev Biol Stand. 1998;95:43-53. Review.

PMID:
9855413
32.

Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice.

Bender BS, Ulmer JB, DeWitt CM, Cottey R, Taylor SF, Ward AM, Friedman A, Liu MA, Donnelly JJ.

Vaccine. 1998 Nov;16(18):1748-55. Erratum in: Vaccine 1999 Mar 17;17(11-12):1581.

PMID:
9778751
33.

Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens.

Fu TM, Guan L, Friedman A, Ulmer JB, Liu MA, Donnelly JJ.

Vaccine. 1998 Nov;16(18):1711-7.

PMID:
9778746
34.
35.

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA.

Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, Caulfield MJ.

J Virol. 1998 Jul;72(7):5648-53.

36.

Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination.

Donnelly JJ, Friedman A, Ulmer JB, Liu MA.

Vaccine. 1997 Jun;15(8):865-8.

PMID:
9234535
37.

Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity.

Ulmer JB, Deck RR, DeWitt CM, Fu TM, Donnelly JJ, Caulfield MJ, Liu MA.

Vaccine. 1997 Jun;15(8):839-41.

PMID:
9234528
38.

Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA.

Mol Med. 1997 Jun;3(6):362-71.

40.

Induction of immunity by DNA vaccination: application to influenza and tuberculosis.

Ulmer JB, Deck RR, DeWitt CM, Donnelly JJ, Friedman A, Montgomery DL, Yawman AM, Orme IM, Denis O, Content J, Huygen K, Liu MA.

Behring Inst Mitt. 1997 Feb;(98):79-86.

PMID:
9382773
41.

New developments in adjuvants.

Donnelly JJ.

Mech Ageing Dev. 1997 Feb;93(1-3):171-7. Review.

PMID:
9089581
42.

DNA vaccines.

Montgomery DL, Ulmer JB, Donnelly JJ, Liu MA.

Pharmacol Ther. 1997;74(2):195-205. Review.

PMID:
9336022
43.

DNA vaccines.

Donnelly JJ, Ulmer JB, Shiver JW, Liu MA.

Annu Rev Immunol. 1997;15:617-48. Review.

PMID:
9143702
44.

Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine.

Deck RR, DeWitt CM, Donnelly JJ, Liu MA, Ulmer JB.

Vaccine. 1997 Jan;15(1):71-8.

PMID:
9041669
45.

DNA vaccines.

Donnelly JJ, Ulmer JB, Liu MA.

Life Sci. 1997;60(3):163-72. Review.

PMID:
9000640
46.

Toward the development of DNA vaccines.

Ulmer JB, Donnelly JJ, Liu MA.

Curr Opin Biotechnol. 1996 Dec;7(6):653-8. Review.

PMID:
8939639
47.

Protection against papillomavirus with a polynucleotide vaccine.

Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA.

J Infect Dis. 1996 Feb;173(2):314-20.

PMID:
8568291
48.

DNA vaccines.

Ulmer JB, Montgomery DL, Donnelly JJ, Liu MA.

Methods Mol Med. 1996;4:289-300. doi: 10.1385/0-89603-334-1:289.

PMID:
21359711
49.

DNA vaccines for bacteria and viruses.

Ulmer JB, Deck RR, Yawman A, Friedman A, Dewitt C, Martinez D, Montgomery DL, Donnelly JJ, Liu MA.

Adv Exp Med Biol. 1996;397:49-53. Review. No abstract available.

PMID:
8718581
50.

Protective efficacy of intramuscular immunization with naked DNA.

Donnelly JJ, Ulmer JB, Liu MA.

Ann N Y Acad Sci. 1995 Nov 27;772:40-6. Review. No abstract available.

PMID:
8546412

Supplemental Content

Loading ...
Support Center